AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12730050 — intervention group
Group type: EXPERIMENTAL
Intervention: 6R‐5,6,7,8‐tetrahydro‐l‐biopterin dihydrochloride (6R‐BH4; n = 10)
Number of subjects: 53
Study 12730050 — intervention group
Group type: COMPARATOR
Intervention: 6S‐5,6,7,8‐tetrahydro‐l‐biopterin sulfate (6S‐BH4; n = 10)
Number of subjects: 53
Study 12730050 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP) infusion
Number of subjects: 53
Study 10988186 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV(1)%pred in the lowest quintile
Number of subjects: 1195
Study 10988186 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV(1)%pred
Number of subjects: 1195
Study 8633669 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 50 microg
Number of subjects: 150
Study 8633669 — intervention group
Group type: EXPERIMENTAL
Intervention: oral contraceptive (50 microg ethinyl estradiol and 250 microg levonogestrel)
Number of subjects: 150
Study 8633669 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 150
Study 1472183 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 39
Study 1472183 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Number of subjects: 39
Study 1472183 — intervention group
Group type: COMPARATOR
Intervention: Sham apheresis
Number of subjects: 39
Study 4018176 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual chest percussion
Number of subjects: 10
Study 4018176 — intervention group
Group type: COMPARATOR
Intervention: Postural drainage and instructed coughing (without percussion)
Number of subjects: 10
Study 29793595 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious sedation
Number of subjects: 128
Study 29793595 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 128
Study 29793595 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 128
Study 29793595 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfused patients subgroup
Number of subjects: 128
Study 27464469 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (6 × 10(9) CFU/day) with vitamins B and C and zinc
Number of subjects: 90
Study 23929004 — intervention group
Group type: EXPERIMENTAL
Intervention: OPAQ-PF (Osteoporosis Assessment Questionnaire-Physical Function)
Number of subjects: 1478
Study 23929004 — intervention group
Group type: COMPARATOR
Intervention: OPAQ v.2.0
Number of subjects: 1478
Study 22555267 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan therapy
Number of subjects: 23
Study 20578829 — intervention group
Group type: EXPERIMENTAL
Intervention: Early CVC removal (within 24 or 48 hours after treatment initiation)
Number of subjects: 842
Study 20578829 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without early CVC removal)
Number of subjects: 842
Study 18308513 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine treatment
Number of subjects: 1996
Study 15777484 — intervention group
Group type: EXPERIMENTAL
Intervention: Below knee cast
Number of subjects: 650
Study 15777484 — intervention group
Group type: EXPERIMENTAL
Intervention: Aircast brace
Number of subjects: 650
Study 15777484 — intervention group
Group type: EXPERIMENTAL
Intervention: Bledsoe boot
Number of subjects: 650
Study 15777484 — intervention group
Group type: COMPARATOR
Intervention: Tubigrip
Number of subjects: 650
Study 12421068 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile and visual stimuli presented in the same hemispace
Number of subjects: 0
Study 12421068 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-choice conditions
Number of subjects: 0
Study 12421068 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased attention to felt texture
Number of subjects: 0
Study 12421068 — intervention group
Group type: EXPERIMENTAL
Intervention: Long presentations of visual stimuli
Number of subjects: 0
Study 10697398 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup A1 (familial history of diabetes without nephropathy)
Number of subjects: 56
Study 10697398 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup A2 (familial history of diabetic nephropathy)
Number of subjects: 56
Study 10697398 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers without familial history)
Number of subjects: 56
Study 8947370 — intervention group
Group type: EXPERIMENTAL
Intervention: Materials-based occupational form (kicking a balloon)
Number of subjects: 45
Study 8947370 — intervention group
Group type: COMPARATOR
Intervention: Imagery-based occupational form (kicking an imaginary balloon)
Number of subjects: 45
Study 8947370 — intervention group
Group type: COMPARATOR
Intervention: Rote exercise (performing a kicking movement without a balloon or imagery prompt)
Number of subjects: 45
Study 8947370 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study 1817616 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide and opioids (n = 24)
Number of subjects: 72
Study 1817616 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide and isoflurane (1, 1.3 and 1.5 MAC for n = 12, 24 and 12, respectively)
Number of subjects: 72
Study 1817616 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsense Words played during anaesthesia
Number of subjects: 72
Study 7034513 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 12
Study 7034513 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 12
Study 31183378 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 604
Study 31183378 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-HDL
Number of subjects: 604
Study 31183378 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertriglyceridemia
Number of subjects: 604
Study 31183378 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 604
Study 31183378 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 604
Study 31183378 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP >11 mg/l
Number of subjects: 604
Study 31183378 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal obesity
Number of subjects: 604
Study 28427593 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb scaffold
Number of subjects: 2008
Study 28427593 — intervention group
Group type: COMPARATOR
Intervention: Xience stent
Number of subjects: 2008
Study 27198842 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluorouracil 1% eye drops, four times a day for 4 weeks
Number of subjects: 98
Study 27198842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 27198842 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluorouracil 1% eye drops
Number of subjects: 98
Study 24492949 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program including daily stretching exercise and twice-a-week muscle endurance training
Number of subjects: 563
Study 24492949 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 563
Study 24492949 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 563
Study 24492949 — intervention group
Group type: COMPARATOR
Intervention: Exercise program and Control group
Number of subjects: 563
Study 23009244 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based management of malaria (HMM) using rapid diagnostic tests (RDTs) and artemisinin-based combination therapy (ACT)
Number of subjects: 12582
Study 23009244 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based management of malaria (HMM)
Number of subjects: 12582
Study 23009244 — intervention group
Group type: COMPARATOR
Intervention: Comparison regions (no HMM implemented until 2010)
Number of subjects: 12582
Study 19502857 — intervention group
Group type: COMPARATOR
Intervention: End-to-end anastomosis
Number of subjects: 139
Study 19502857 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-to-side anastomosis
Number of subjects: 139
Study 17220780 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose (CMC)
Number of subjects: 30
Study 17220780 — intervention group
Group type: COMPARATOR
Intervention: Povidone
Number of subjects: 30
Study 15896615 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG with antegrade blood cardioplegia (Group A)
Number of subjects: 262
Study 15896615 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade and retrograde blood cardioplegia (Group B)
Number of subjects: 262
Study 15896615 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG (Group C)
Number of subjects: 262
Study 11952582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure
Number of subjects: 40
Study 11952582 — intervention group
Group type: COMPARATOR
Intervention: Conventional diathermy
Number of subjects: 40
Study 9798806 — intervention group
Group type: EXPERIMENTAL
Intervention: Otilonium bromide 40 mg t.d.s.
Number of subjects: 325
Study 9798806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 7539184 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (alpha 1 blockade + androgen suppression)
Number of subjects: 0
Study 7539184 — intervention group
Group type: COMPARATOR
Intervention: Monotherapies
Number of subjects: 0
Study 1899776 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of recombinant tissue-type plasminogen activator (rt-PA)
Number of subjects: 100
Study 1899776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1899776 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 100
Study 6521474 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol group (N=10)
Number of subjects: 23
Study 6521474 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (N=13)
Number of subjects: 23
Study 31140358 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractions intervention with embedded self-regulation (SR)
Number of subjects: 69
Study 31140358 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractions intervention without embedded self-regulation (SR)
Number of subjects: 69
Study 31140358 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual control
Number of subjects: 69
Study 29414542 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 50mg/day with concomitant lamotrigine (LTG)
Number of subjects: 342
Study 29414542 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 100mg/day with concomitant lamotrigine (LTG)
Number of subjects: 342
Study 29414542 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 200mg/day with concomitant lamotrigine (LTG)
Number of subjects: 342
Study 29414542 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 50mg/day with concomitant topiramate (TPM)
Number of subjects: 342
Study 29414542 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 100mg/day with concomitant topiramate (TPM)
Number of subjects: 342
Study 29414542 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 200mg/day with concomitant topiramate (TPM)
Number of subjects: 342
Study 29414542 — intervention group
Group type: COMPARATOR
Intervention: Placebo with concomitant lamotrigine (LTG)
Number of subjects: 342
Study 29414542 — intervention group
Group type: COMPARATOR
Intervention: Placebo with concomitant topiramate (TPM)
Number of subjects: 342
Study 29414542 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) ≥50mg/day with concomitant lamotrigine (LTG)
Number of subjects: 342
Study 29414542 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) ≥50mg/day with concomitant topiramate (TPM)
Number of subjects: 342
Study 29414542 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) ≥50mg/day
Number of subjects: 342
Study 29414542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study 27261222 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate (CC) after a withdrawal bleed induced by Medroxyprogesterone Acetate (MPA) 10 mg daily for 10 days
Number of subjects: 0
Study 27261222 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene Citrate (CC) without a preceding withdrawal bleed
Number of subjects: 0
Study 25248813 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 36
Study 25248813 — intervention group
Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT)
Number of subjects: 36
Study 25248813 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AIT and MCT
Number of subjects: 36
Study 22211798 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 63
Study 22211798 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 63
Study 22211798 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 63
Study 21258125 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine (50 µg daily, increased as necessary)
Number of subjects: 56
Study 21258125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 18055673 — intervention group
Group type: EXPERIMENTAL
Intervention: Green beans and peaches (combined exposure)
Number of subjects: 45
Study 18055673 — intervention group
Group type: COMPARATOR
Intervention: Green beans (alone)
Number of subjects: 45
Study 18055673 — intervention group
Group type: EXPERIMENTAL
Intervention: Peaches (alone)
Number of subjects: 45
Study 18055673 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 45
Study 18055673 — intervention group
Group type: COMPARATOR
Intervention: Formula feeding
Number of subjects: 45
Study 16255377 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented wheat germ extract
Number of subjects: 170
Study 16255377 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 170
Study 11879212 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon (Xe)
Number of subjects: 10
Study 11879212 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide (N2O)
Number of subjects: 10
Study 9334897 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH, 0.6 mg/kg)
Number of subjects: 22
Study 9334897 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral contingencies (reward plus response cost)
Number of subjects: 22
Study 9334897 — intervention group
Group type: COMPARATOR
Intervention: Placebo + feedback
Number of subjects: 22
Study 9334897 — intervention group
Group type: COMPARATOR
Intervention: Placebo + behavioral contingencies
Number of subjects: 22
Study 9334897 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH + feedback
Number of subjects: 22
Study 9334897 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH + contingencies
Number of subjects: 22
Study 8493493 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium infusion (0.5 g glucose, 1.35 IU insulin, 0.25 mmol/kg b.w/hour)
Number of subjects: 7
Study 8493493 — intervention group
Group type: COMPARATOR
Intervention: Control group (no infusion)
Number of subjects: 7
Study 8493493 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium infusion
Number of subjects: 7
Study 8493493 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7
Study 8493493 — intervention group
Group type: COMPARATOR
Intervention: Glucose-insulin-potassium infusion and Control group
Number of subjects: 7
Study 3121928 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (4 mg bolus followed by 2 mg/h infusion for 4 h)
Number of subjects: 10
Study 3121928 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen administration
Number of subjects: 10
Study 3121928 — intervention group
Group type: COMPARATOR
Intervention: ACTH 1-24 (250 micrograms i.v.)
Number of subjects: 10
Study 3121928 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg)
Number of subjects: 10
Study 29796913 — intervention group
Group type: EXPERIMENTAL
Intervention: Angle of His accentuation (AOH)
Number of subjects: 110
Study 29796913 — intervention group
Group type: COMPARATOR
Intervention: Dor Fundoplication (Dor)
Number of subjects: 110
Study 26423617 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise rehabilitation
Number of subjects: 37
Study 26423617 — intervention group
Group type: COMPARATOR
Intervention: Delayed exercise programme (usual care group post-intervention)
Number of subjects: 37
Study 24577154 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person delivery by a board-certified genetic counselor
Number of subjects: 300
Study 24577154 — intervention group
Group type: COMPARATOR
Intervention: Online delivery through the testing company's website
Number of subjects: 300
Study 22148098 — intervention group
Group type: COMPARATOR
Intervention: 75 mg/day aspirin
Number of subjects: 48
Study 22148098 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg/day aspirin
Number of subjects: 48
Study 22148098 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg/day aspirin in patients with poor glycemic control
Number of subjects: 48
Study 22148098 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg/day aspirin in patients with good glycemic control
Number of subjects: 48
Study 20047675 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based education/support group program
Number of subjects: 8
Study 20047675 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 8
Study 18500609 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 200 microg
Number of subjects: 90
Study 18500609 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate 100 mg
Number of subjects: 90
Study 18500609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 15842150 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) for chronic disease treatment
Number of subjects: 0
Study 15842150 — intervention group
Group type: EXPERIMENTAL
Intervention: SCRCT (Single Case Randomized Controlled Trial)
Number of subjects: 0
Study 12939207 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg twice daily)
Number of subjects: 4048
Study 12939207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4048
Study 12939207 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 4048
Study 10947550 — intervention group
Group type: EXPERIMENTAL
Intervention: New style care (reduced schedule of visits)
Number of subjects: 2794
Study 10947550 — intervention group
Group type: COMPARATOR
Intervention: Traditional care (traditional antenatal visiting schedule)
Number of subjects: 2794
Study 8638453 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg intravenous dehydroepiandrosterone sulfate (DHAS) in 20 ml of 5% dextrose
Number of subjects: 10
Study 8638453 — intervention group
Group type: COMPARATOR
Intervention: 20 ml 5% dextrose (control)
Number of subjects: 10
Study 8638453 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg intravenous dehydroepiandrosterone sulfate (DHAS)
Number of subjects: 10
Study 1365017 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF in patients receiving positively selected marrow
Number of subjects: 0
Study 4072957 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation for 3 months
Number of subjects: 119
Study 4072957 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 119
Study 4072957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 31721670 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative wound pressure therapy (NPWT)
Number of subjects: 24
Study 31721670 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication with health professionals
Number of subjects: 24
Study 29395361 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 9148
Study 29395361 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 9148
Study 29395361 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse event interruption
Number of subjects: 9148
Study 29395361 — intervention group
Group type: COMPARATOR
Intervention: No interruption
Number of subjects: 9148
Study 26473281 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 92
Study 24496805 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention for 12 months (n = 181)
Number of subjects: 360
Study 24496805 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (educational materials mailed at 4‐month intervals, preceded by phone calls, n = 179)
Number of subjects: 360
Study 24496805 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention
Number of subjects: 360
Study 24496805 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone contacts within the CHW intervention
Number of subjects: 360
Study 23043193 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental hyperglycemia (+5.4 mm above basal) in normal glucose‐tolerant subjects for 24 hours
Number of subjects: 20
Study 23043193 — intervention group
Group type: COMPARATOR
Intervention: Type 2 diabetes (no intervention)
Number of subjects: 20
Study 20158620 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal clonidine (2 microg x kg(‐1)) + caudal 0.25% levobupivacaine
Number of subjects: 60
Study 20158620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (2 microg x kg(‐1)) + caudal 0.25% levobupivacaine
Number of subjects: 60
Study 20158620 — intervention group
Group type: COMPARATOR
Intervention: Caudal 0.25% levobupivacaine + i.v. saline
Number of subjects: 60
Study 18629586 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoluminal gastroplication (ELGP) with adjuvant bicap cautery
Number of subjects: 18
Study 18629586 — intervention group
Group type: COMPARATOR
Intervention: Endoluminal gastroplication (ELGP) without cautery
Number of subjects: 18
Study 18629586 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoluminal gastroplication (ELGP) with or without cautery
Number of subjects: 18
Study 16273784 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease modifying drugs and biologic agents
Number of subjects: 0
Study 16273784 — intervention group
Group type: EXPERIMENTAL
Intervention: Early steroid therapy
Number of subjects: 0
Study 16273784 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive therapy with disease modifying drugs
Number of subjects: 0